Compounds that modulate the estrogen receptor (ER) are disclosed, as well
as pharmaceutical compositions containing the same. In a specific
embodiment, the compounds are selective modulators for ER-.beta. over
ER-.alpha.. Methods are disclosed for modulating ER-.beta. in cell and/or
tissues expressing the same, including cells and/or tissue that
preferentially express ER-.beta.. More generally, methods for treating
estrogen-related conditions are also disclosed, including conditions such
as is breast cancer, testicular cancer, osteoporosis, endometriosis,
cardiovascular disease, hypercholesterolemia, prostatic hypertrophy,
prostatic carcinomas, obesity, hot flashes, skin effects, mood swings,
memory loss, urinary incontinence, hairloss, cataracts, natural hormonal
imbalances, and adverse reproductive effects associated with exposure to
environmental chemicals.